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Abstract
Aggresome formation, a cellular response to misfolded protein aggregates, is linked to cancer and 
neurodegenerative disorders. Previously we showed that Gag-v-ErbA (v-ErbA), a retroviral 
variant of the thyroid hormone receptor (TRα1), accumulates in and sequesters TRα1 into 
cytoplasmic foci. Here, we show that foci represent v-ErbA targeting to aggresomes. v-ErbA 
colocalizes with aggresomal markers, proteasomes, hsp70, HDAC6, and mitochondria. Foci have 
hallmark characteristics of aggresomes: formation is microtubule-dependent, accelerated by 
proteasome inhibitors, and they disrupt intermediate filaments. Proteasome-mediated degradation 
is critical for clearance of v-ErbA and T3-dependent TRα1 clearance. Our studies highlight v-
ErbA’s complex mode of action: the oncoprotein is highly mobile and trafficks between the 
nucleus, cytoplasm, and aggresome, carrying out distinct activities within each compartment. 
Dynamic trafficking to aggresomes contributes to the dominant negative activity of v-ErbA and 
may be enhanced by the viral Gag sequence. These studies provide insight into novel modes of 
oncogenesis across multiple cellular compartments.
Keywords
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1. Introduction
The retroviral Gag-v-ErbA oncoprotein (p75gag-v-erb-A) is a highly mutated variant of the 
thyroid hormone receptor α1 (c-ErbA or TRα1), which is unable to bind thyroid hormone 
(T3) and interferes with the action of TRα1 and the retinoic acid receptor in avian and 
mammalian cancer cells. Since the discovery of v-erbA as one of the oncogenes carried by 
the avian erythroblastosis virus (AEV), researchers have focused on the oncoprotein’s 
complex mode of action in cells, with an emphasis on relating changes in amino acid 
sequence to its nuclear function (Beug et al., 1996; Thormeyer and Baniahmad, 1999). 
Theamino acid sequence changes which contribute to its oncogenic properties include fusion 
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of a portion of AEV Gag to its N-terminus, N- and C-terminal deletions, and 13 amino acid 
substitutions. The avian c-erbA gene was likely fused to gag either by homologous 
recombination within the host cell genome or during retrotranscription of c-erbA mRNA 
packaged into retrovirus particles (Sap et al., 1986). For simplicity, we refer to the Gag-v-
ErbA oncoprotein as v-ErbA hereinafter.
Early on, v-ErbA dominant-negative activity was attributed to competition with TRα1 for 
T3-responsive DNA elements and/or auxiliary factors involved in the transcriptional 
regulation of T3-responsive genes. It is now known that oncogenic conversion of v-ErbA 
from its cellular homolog not only involves changes in DNA binding specificity and ligand 
binding properties, but also the acquisition of altered nuclear export capabilities and changes 
in subcellular localization (Bonamy and Allison, 2006). As part of our studies, we noted that 
v-ErbA and other dominant negative variants of TR have a greater cytoplasmic localization 
compared with the wild-type receptor and often show a punctate distribution in cytoplasmic 
or nuclear foci (Bonamy et al., 2005; Bunn et al., 2001; DeLong et al., 2004). Even single 
amino acid substitutions in TR are sufficient to shift its balance to a more cytoplasmic 
distribution. Previously, we showed that dominant negative variants of another TR isoform, 
TRβ, which carry single amino acid substitutions in the DNA-binding domain (Gly121Ala 
and Cys122Ala), form perinuclear cytoplasmic foci (Bunn et al., 2001). Interestingly, this 
distribution pattern is very similar to the pattern described for a TRα dominant negative 
mutant in which the entire hinge, or D, domain was deleted (Lee and Mahdavi, 1993).
Upon further analysis of v-ErbA trafficking, we made a surprising discovery. Wild-type 
TRα1 is primarily nuclear at steady-state (Bunn et al., 2001); however, when co-expressed 
with v-ErbA there is a striking and dramatic shift in the distribution pattern of TRα1 
(Bonamy et al., 2005). v-ErbA dimerizes with TRα1 and the retinoid X receptor, and 
sequesters a significant fraction of the two nuclear receptors in the cytoplasm (Bonamy et 
al., 2005). These results defined a new mode of action of v-ErbA, and illustrated the 
importance of cellular compartmentalization in transcriptional regulation (Bonamy and 
Allison, 2006). Our findings were closely followed by a report defining a cytoplasmic 
function for v-ErbA, whereby the oncoprotein sequesters Smad4 into the cytoplasm and 
disrupts the transforming growth factor-β (TGF-β) pathway (Erickson and Liu, 2009). To 
further explore the cytoplasmic activities of v-ErbA, we sought to ascertain the nature of the 
cytoplasmic foci formed by a subpopulation of v-ErbA.
Newly synthesized proteins must fold correctly to become functional. When the protein is 
misfolded, hydrophobic residues that are normally buried in the protein’s interior are 
exposed leading to protein aggregation. Cells have evolved quality control systems that are 
conserved from yeast to mammalian cells to minimize protein misfolding and prevent 
protein aggregation (Bagola and Sommer, 2008). Molecular chaperones such as the heat 
shock proteins assist in refolding misfolded proteins, and bind to and stabilize exposed 
hydrophobic residues thereby reducing the likelihood of protein aggregation (Bercovich et 
al., 1997; Dul et al., 2001; Morimoto, 2008; Schroder and Kaufman, 2005). Alternatively, 
misfolded and aggregated proteins are destroyed by the ubiquitin-mediated proteasome 
degradation pathway (Pankiv et al., 2007; Ross and Poirier, 2004; Rubinsztein, 2006) or 
through the autophagy-lysosome system (Iwata et al., 2005; Levine and Kroemer, 2008; 
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Mizushima et al., 2008; Mortimore et al., 1996). Recent evidence suggests that cells have 
another important quality control pathway in which aggregated proteins are specifically 
delivered to inclusion bodies by dynein-dependent retrograde transport on microtubules. 
This microtubule-dependent inclusion body is called an aggresome (Garcia-Mata et al., 
2002; Johnston et al., 1998; Kawaguchi et al., 2003; Kopito, 2000; Zhou et al., 2009). To 
promote disposal of the aggregated material, cytoplasmic aggresomes recruit chaperones and 
proteasomes, or trigger autophagy. In addition to waste disposal systems for the 
accumulation of aggregated proteins, aggresomes can also function as sites for viral 
replication and assembly (Wileman, 2006, 2007). Dysregulation of these mechanisms for 
degradation of misfolded or mutant proteins has been implicated in numerous clinical 
diseases, including cystic fibrosis, neurodegenerative disorders, and cancer (Heir et al., 
2006; Iwata et al., 2005; Kitami et al., 2006; Ma and Lindquist, 2001; Olzmann and Chin, 
2008; Riley et al., 2002; Ross and Poirier, 2004; Sha et al., 2009; Shimohata et al., 2002; 
Simms-Waldrip et al., 2008).
Here, we provide evidence for targeting of the oncoprotein v-ErbA to aggresomes. We have 
shown that v-ErbA foci display aggresomal characteristics by documenting the 
colocalization of v-ErbA inclusions with aggresome, proteasome, and mitochondrial 
markers as well as the dependence of the trafficking of these inclusions upon the dynein/
dynactin motor and microtubules. Our studies offer insight into how cytoplasmic 
mislocalization of TRα1 by v-ErbA into aggresomes may contribute to oncogenesis. 
Association of a viral oncoprotein with these specialized quality control compartments 
provides further insight into the generality of this mechanism of aggresome trafficking for 
dealing with mutant proteins.
2. RESULTS
2.1 A subpopulation of the oncoprotein v-ErbA localizes to punctate foci in erythroblasts 
transformed with AEV
Prior studies had shown that v-ErbA expressed in transfected mammalian cell lines has a 
range of distributions from whole cell (with a nuclear subpopulation) to a mainly 
cytoplasmic distribution, localized in punctate, perinuclear foci suggestive of aggresome-
like inclusions (Bonamy et al., 2005; Bunn et al., 2001). These observations raised the 
question of whether this localization in transfected cells adequately recapitulates the 
distribution of the native, virally-expressed v-ErbA. Since v-ErbA was originally isolated 
from chicken erythroblast cells, we used HD3 cells to investigate the distribution of native 
v-ErbA. HD3 cells are chicken erythroblasts transformed by AEV that express both native 
v-ErbA and v-ErbB (Erickson and Liu, 2009). After immunostaining with anti-v-ErbA/c-
ErbA antibodies, HD3 cells were visualized by fluorescence microscopy. HD3 cells are 
semi-adherent cells with a rounded-up morphology and less visible cytoplasm compared 
with fully-adherent HeLa cells (Fig. 1). Despite these differences in morphology, 
cytoplasmic foci of virally-expressed v-ErbA were still readily apparent in these AEV-
transformed cells (Fig. 1B). As in HeLa cells (Fig. 1A), v-ErbA was present throughout the 
cell, with both nuclear and cytoplasmic subpopulations. These findings thus suggest that 
aggresome-like inclusions are not an artefact of v-ErbA expression in transfected 
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mammalian cells. Similar cytoplasmic inclusions are present in AEV-infected erythroblasts, 
where v-ErbA acts as a potent enhancer of cellular transformation (Beug et al., 1996).
2.2 The oncoprotein v-ErbA colocalizes with aggresomal markers
Previously we showed that v-ErbA cytoplasmic foci do not represent localization of variants 
to membrane-bound cellular organelles and are not an artefact of the GFP tag or 
overexpression (Bonamy et al., 2005). To further confirm that overexpression of fluorescent 
protein-tagged fusion proteins does not lead to aggresome formation by a non-specific 
mechanism, we tested a panel of fluorescent proteins for their localization after transfection 
into HeLa cells (Fig. 2A). No cytoplasmic foci were observed for any of the fluorescent 
proteins or tagged fusion proteins analyzed. GFP, DsRed2, and Dendra were distributed 
diffusely throughout the whole cell; the fusion protein GFP-GST-GFP was diffusely 
distributed throughout the cytoplasm; and, in the absence of ligand, GFP-tagged 
glucocorticoid receptor was localized primarily to the cytoplasm in a diffuse distribution 
pattern.
These findings point to the possibility that cytoplasmic foci could represent specific 
targeting of v-ErbA to aggresomes. Besides aggresome formation, other protein aggregation 
pathways also appear to exist in mammalian cells (Zaarur et al., 2008). Thus, to confirm that 
v-ErbA aggregates are bona fide aggresomes, we conducted definitive cotransfection assays 
with fluorescently-tagged fusion proteins. Cytoplasmic foci were observed for DsRed2-
tagged v-ErbA, as well as for v-ErbA tagged with Dendra2, a monomeric fluorescent protein 
(Fig. 2B).
Characteristics of aggresomes are portrayed by the protein chimeras GFP-250 and GFP170*. 
GFP-250 is composed of GFP fused at its C-terminus to the first 250 amino acids of p115, a 
protein involved in the transport of cargo from the endoplasmic reticulum to the Golgi 
(Nelson et al., 1998). GFP170* is composed of GFP fused to amino acids 566–1375 of the 
Golgi Complex Protein (GCP)-170 (Fu et al., 2005; Hicks and Machamer, 2002). In 
previous studies, overexpression of GFP-250 was shown to result in a spherical aggregate at 
the MTOC, similar to those formed by other cellular proteins (Garcia-Mata et al., 1999). We 
observed comparable aggregates in HeLa cells transfected with GFP-250 expression plasmid 
(Fig. 2C). To investigate whether or not the foci formed by v-ErbA colocalized with 
aggresomal markers, HeLa cells were cotransfected with GFP-250 and DsRed2-tagged v-
ErbA expression plasmids and their subcellular localizations were observed (Fig. 2D). Cells 
were fixed both 24 h and 48 h post-transfection to observe the dynamics of aggresome 
formation. After 24 h, cells cotransfected with DsRed2-v-ErbA and GFP-250 contained 
smaller more dispersed aggregates of both proteins throughout the cytoplasm. There was a 
high degree of colocalization between these small aggregates, suggesting that both of these 
proteins follow the same dynamic pathway. After 48 h, the cells contained larger coalesced 
aggregates of both GFP-250 and DsRed2-v-ErbA. DsRed2-v-ErbA and GFP-250 completely 
colocalized in 59 ± 4% of cells and partially colocalized in 38 ± 4% of cells (Fig. 2D and 
2E). These results strongly suggest that DsRed2-v-ErbA and GFP-250 are targeted to the 
same subcellular compartment, despite their slight differences in morphology. In contrast to 
GFP 250, GFP170* forms large “ribbon-like” aggregates at the MTOC and punctate foci in 
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the nucleus (Fu et al., 2005). These nuclear inclusions codistribute with promyelocytic 
leukemia (PML) bodies and have been referred to as nuclear aggresomes (Fu et al., 2005). 
DsRed2-v-ErbA also colocalized with the cytoplasmic aggregates formed by GFP170* (Fig. 
2D). Taken together, these data provide strong evidence for association of v-ErbA with 
aggresomes.
2.3 Formation and movement of v-ErbA inclusions is microtubule- and dynein-dependent
After demonstrating that v-ErbA colocalized with the aggresomal markers GFP-250 and 
GFP170*, we next sought to ascertain whether v-ErbA foci possess other hallmark 
characteristics of aggresomes. Aggresome formation occurs when small aggregates of 
misfolded and defective proteins travel in a minus-end direction along the microtubule 
tracks towards the MTOC. Thus, microtubule disruption by the drug nocodazole prevents 
bona fide aggresome formation (Fu et al., 2005; Garcia-Mata et al., 1999; Garcia-Mata et al., 
2002).
Nocodazole disrupts microtubules by preventing their polymerization. The drug binds to a 
sulfhydryl group on β-tubulin, prevents disulfide linkages with additional tubulin 
heterodimers and inhibits transport of cargo and cell division (Luduena and Roach, 1991; 
Vasquez et al., 1997). First, to confirm that nocodazole had an inhibitory effect upon the 
microtubule network in our system, untransfected cells were either treated with nocodazole 
or DMSO (vehicle control), or left untreated. The cells were then stained with anti-β-tubulin 
to visualize the microtubules. Cells that were untreated or treated with DMSO displayed a 
fibrous, wispy network of microtubules that spanned the whole cell (Fig. 3A). However, 
those cells that had been treated with nocodazole lacked the fibrous network that existed in 
untreated cells, indicating that the microtubule network was disrupted.
Next, to determine whether the disruption of microtubules would prevent the formation of 
the coalesced foci, 16 h post-transfection HeLa cells expressing GFP-v-ErbA were treated 
with nocodazole for 20 h. If aggresome formation was inhibited, one would expect to see a 
diffuse expression pattern or a dispersal of small aggregates throughout the cytoplasm. As 
predicted, treatment of GFP-v-ErbA-expressing cells with nocodazole resulted in a majority 
of cells with a diffuse pattern of v-ErbA expression (Fig. 3B). Only 13 ± 3% of untreated 
cells contained diffuse aggregates (Fig. 3C). Upon nocodazole treatment, there was a 
significant shift (p<0.001) to 55 ± 3% of cells containing diffuse aggregates. While 46 ± 5% 
of untreated v-ErbA-expressing cells contained large aggregates, only 7 ± 3% of 
nocodazole-treated cells had large aggregates. Because nocodazole cannot disrupt 
aggregates that are already intact prior to treatment, many of the aggregates observed in 
treated cells could have been preexisting. Movement of v-ErbA pre-aggresomal structures to 
the nuclear periphery was also demonstrated by live cell imaging (see Video S2 in the 
supplemental material). Taken together, data thus suggest that over time, v-ErbA aggregates 
are transported via microtubule motors and coalesce in a perinuclear structure.
The dynein/dynactin complex serves as a minus-end (retrograde) directed motor that 
transports cargo, including aggregates of misfolded proteins, along the microtubule tracks 
from the cell periphery to the MTOC. Aggresomes form when these smaller aggregates 
reach the MTOC (Melkonian et al., 2007). Dynactin is a multiprotein complex that is 
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required for the majority of dynein-based movement in vivo. One subunit of dynactin, p50/
dynamitin, is directly involved in the attachment of cargo to dynein. Overexpression of p50/
dynamitin is known to dissociate the dynein/dynactin complex and, thereby, reduces the 
extent of aggresome formation and sequesters proteins into pre-aggresomal structures 
(Garcia-Mata et al., 2002; Johnston et al., 2002; Melkonian et al., 2007; Sha et al., 2009). 
Thus, disruption of the formation of v-ErbA foci by overexpression of p50/dynamitin would 
provide further evidence of the aggresomal nature of these aggregates.
Cells were transfected with GFP-250 as a control or GFP-v-ErbA expression plasmid, either 
alone or together with p50/dynamitin expression plasmid. Consistent with published reports 
(Garcia-Mata et al., 2002), 27% of cells expressing GFP-250 alone contained fully formed 
aggresomes, while 73% contained small aggregates (Fig. 3D and 3E). In contrast, 13% of 
cells cotransfected with GFP-250 and p50/dynamitin expression plasmids contained fully-
formed aggresomes and 87% contained small aggregates.
Similar to the pattern observed for GFP-250, 49% of cells expressing v-ErbA alone 
contained aggresomes, while 51% contained small aggregates (Fig. 3F and 3G). In contrast, 
approximately 26% of cells cotransfected with GFP-v-ErbA and p50/dynamitin expression 
plasmids contained aggresomes and 74% contained small aggregates. Taken together, these 
findings provide evidence that formation of v-ErbA-containing aggresomes is mediated by 
the dynein/dynactin motor protein complex.
2.4 v-ErbA inclusions cause a disruption of vimentin intermediate filaments and recruit 
histone deacetylase 6 (HDAC6)
A number of aggresome-forming misfolded proteins and viral particles have been shown to 
cause a collapse of the intermediate filament meshwork composed of vimentin into a 
circular vimentin “cage” around the area of aggregated protein for immobilization and 
containment (Fu et al., 2005; Garcia-Mata et al., 1999; Heath et al., 2001; Johnston et al., 
1998). Since v-ErbA has a more “ribbon-like” (as defined by Fu et al., 2005) morphology in 
the absence of proteasome inhibition, the formation of a circular “cage” around the area of 
aggregated protein was not predicted. To determine whether v-ErbA foci caused some type 
of disruption of vimentin, cells transfected with GFP-v-ErbA were stained with a Cy3-
conjugated antibody against vimentin 48 h post-transfection. In untransfected cells, the 
vimentin distribution pattern was filamentous and dispersed throughout the cell (Fig. 4A). 
However, cells transfected with GFP-v-ErbA showed a reorganization and collapse of 
vimentin filaments around the area of aggregated protein (Fig. 4B). These results provide 
additional evidence that v-ErbA foci exhibit aggresomal characteristics.
Dynein-mediated transport of cargo to aggresomes is necessary for their formation. In some 
cases aggresomes also appear to become enriched in dynein (Diaz-Griffero et al., 2006; 
Johnston et al., 2002; Szebenyi et al., 2007). Thus, we tested for colocalization of the 
aggresomal marker GFP-250 (Fig. 4C) and GFP-v-ErbA (Fig. 4D) with dynein, by 
immunostaining of transfected cells with anti-dynein antibodies. Some cells were treated 
with the proteasome inhibitor MG132 for 20 h prior to fixation, in order to increase the 
amount of mature aggresome formation compared to pre-aggresomal structures in untreated 
cells (Fig. 4C and 4D, lower panels). No distinct colocalization was observed between 
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GFP-250 or GFP-v-ErbA and dynein in either untreated or MG132-treated cells. Data thus 
suggest that for these particular cargo types, the dynein/dynactin motor complex does not 
accumulate in aggresomes to any significant degree.
We next sought to ascertain whether v-ErbA inclusions colocalize with the tubulin 
deacetylase, histone deacetylase 6 (HDAC6), another key marker characteristic of 
aggresomes (Boyault et al., 2007; Iwata et al., 2005; Rodriguez-Gonzalez et al., 2008). Most 
HDACs are localized to the nucleus and play a role in transcriptional repression (Suzuki, 
2009). HDAC6 is unusual in that it is localized to the cytoplasm and mediates deacetylation 
of non-histone proteins, including α-tubulin (Olzmann and Chin, 2008; Sha et al., 2009). Of 
the eighteen HDACs identified so far, only HDAC6 has been shown to be involved in 
regulation of aggresome function (Suzuki, 2009).
To investigate whether or not GFP-250 and GFP-v-ErbA-containing aggresomes colocalized 
with HDAC6, HeLa cells were transfected with either GFP-250 or GFP-v-ErbA expression 
vectors. Twenty four hours post transfection, cells were fixed and stained with anti-HDAC6 
antibodies and the subcellular localizations of proteins were observed. Colocalization with a 
subpopulation of HDAC6 was evident in GFP-250-expressing cells that contained fully-
formed aggresomes (Fig. 4E). Colocalization with a subpopulation of HDAC6 was also 
observed in cells expressing GFP-v-ErbA (Fig. 4F); correlating with the formation of large, 
perinuclear aggresomes.
2.5 Proteasome inhibition enhances the size of v-ErbA aggresomes but does not induce 
cytoplasmic aggregates of TRα1
The inhibition of proteasome activity typically leads to an increase in aggresome size (Fu et 
al., 2005; Garcia-Mata et al., 1999; Johnston et al., 1998). To determine whether the size of 
v-ErbA foci would increase in response to proteasome inhibition, cells expressing GFP-v-
ErbA were treated 16 h post-transfection with the proteasome inhibitor MG132 for 20 h. 
MG132 blocks proteasome degradation by inhibiting the chymotrypsin-like activity of the 
proteasome, preventing the cleavage of peptide bonds within the target protein (Lee and 
Goldberg, 1998).
As predicted, MG132 treatment dramatically increased the size of v-ErbA foci. 
Interestingly, most of the large aggregates were spherical in morphology and coalesced into 
a single aggregate (Fig. 5A, right panel), similar to the spherical aggresomes formed by 
GFP-250, mutant huntingtin protein (Kuemmerle et al., 1999) and mutant cystic fibrosis 
transmembrane conductance regulator (CFTR) (Johnston et al., 1998) after proteasome 
inhibition. In contrast, in the absence of MG132, v-ErbA inclusions were “ribbon-like” (as 
defined by Fu et al., 2005) in morphology or consisted of multiple, smaller aggregates (Fig. 
5A, left panel). Since improper folding of proteins can occur as a result of high levels of 
protein expression (Olzmann and Chin, 2008), we also analyzed the localization of GFP. No 
foci or aggregates were seen in cells expressing GFP alone, although there was a slight 
increase in the intensity of GFP fluorescence in cells treated with MG132 (data not shown).
In addition to an increase in the size of aggregates, v-ErbA-expressing cells treated with 
MG132 showed more intense fluorescence when compared with untreated cells, suggesting 
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that there was an increase in cellular levels of v-ErbA as a result of inhibition of proteasome 
activity. Quantification of replicate experiments showed that only 41 ± 2% of untreated cells 
contained large aggregates of GFP-v-ErbA, but upon MG132 treatment, there was a 
significant shift (p<0.001) to 78 ± 7% of v-ErbA-expressing cells containing large 
aggregates (Fig. 5B).
To confirm that the increase in v-ErbA aggregate size was due to an increase in total protein 
and not just the coalescence of pre-existing smaller aggregates, we carried out immunoblot 
analysis of v-ErbA expression levels in HeLa cells. Immunoblot analysis showed a greater 
accumulation of GFP-v-ErbA in MG132-treated transfected cells compared with untreated 
(Fig. 5C). Taken together, these results suggest that the proteasome machinery normally 
degrades some of the aggregated v-ErbA, thus preventing formation of mature aggresomes 
in all cells.
In contrast to the oncoprotein v-ErbA, cytoplasmic foci are not observed when the cellular 
homolog TRα1 is over-expressed in mammalian cells (Bonamy et al., 2005). For some other 
proteins, such as malin and laforin, where <8% of transfected cells show aggregates, 
proteasome inhibition is required to induce formation of aggregates (Mittal et al., 2007). 
Thus, we sought to ascertain whether treatment with MG132 would induce cytoplasmic 
inclusions of TRα1. Prior studies have shown that T3-binding induces rapid proteasome-
mediated degradation of endogenous or untagged, exogenous TRα1 in GC cells (growth 
hormone-producing rat pituitary tumor cell line) (Dace et al., 2000) and in cardiomyocytes 
(Kenessey and Ojamaa, 2005). This mechanism of receptor downregulation appears to be 
conserved among the nuclear receptor superfamily and has been proposed to be an important 
mechanism by which receptor signaling can be regulated (Kenessey and Ojamaa, 2005). To 
determine whether GFP-tagged TRα1 is also subject to proteasome-mediated degradation, 
we carried out both in situ and immunoblot analysis in HeLa cells.
Immunoblot analysis showed a greater accumulation of GFP-TRα1 in MG132-treated 
transfected cells compared with untreated (Fig. 5D). Strikingly, proteasome-mediated 
degradation of GFP-tagged TRα1 was much more rapid in cells treated with T3 than in the 
absence of hormone. Thyroid hormone had no effect on GFP-v-ErbA and EGFP turnover 
rates (data not shown). For analysis of proteasome-mediated degradation of TRα1 in situ, 
cells were transfected with expression vectors for GFP-TRα1. Cells treated with T3 showed 
much fainter nuclear fluorescence of GFP-TRα1 compared with untreated cells (Fig. 5E). In 
contrast, cells treated with proteasome inhibitor had a greater level of protein expression and 
often had large foci within the nucleus (Fig. 5F). Taken together, these findings indicate that 
like the oncoprotein v-ErbA, TRα1 undergoes proteasome-mediated degradation, and that 
degradation of TRα1 is much more rapid in the presence of ligand. However, treatment with 
MG132 does not induce cytoplasmic inclusions of TRα1.
2.6 v-ErbA aggresomes recruit proteasomes and cellular chaperones
Formation of aggresomes has been reported to involve the recruitment of cytosolic 
components, including chaperones, ubiquitination enzymes, and proteasome subunits, to 
facilitate clearance of aggregated proteins (Fu et al., 2005; Garcia-Mata et al., 2002; Mittal 
et al., 2007; Waelter et al., 2001); however, this proteasome recruitment does not necessarily 
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require ubiquitination of aggresome components (Garcia-Mata et al., 2002). To further 
characterize foci formed by v-ErbA as aggresomes, we investigated the association of 
proteasomes, Hsp70 and ubiquitin with v-ErbA.
To investigate GFP-v-ErbA cytoplasmic inclusions and their potential colocalization with 
proteasomes, we transfected cells with expression vectors for either GFP-250 or GFP-v-
ErbA (Fig. 6A). After immunostaining with anti-20S proteasome subunit antibodies (the 
catalytic core of the 26S proteasome), cells were observed by fluorescence microscopy. 
Some cells were treated with MG132 in order to increase the amount of mature aggresome 
formation compared to pre-aggresomal structures in untreated cells. We first investigated the 
colocalization of the aggresomal marker GFP-250 with proteasomes. 20S proteasome 
subunits showed a diffuse distribution throughout the cytoplasm; however, 59% of cells with 
GFP-250 aggregates displayed distinct colocalization of a subpopulation of 20S proteasome 
subunits with these aggregates (Fig. 6A, upper panels). Of the cells that were overexpressing 
GFP-v-ErbA, 68% of those that formed aggresomes showed colocalization with a 
subpopulation of 20S proteasome subunits (Fig. 6A, lower panels).
To investigate GFP-v-ErbA cytoplasmic inclusions and their colocalization with Hsp70 and 
ubiquitin, Hela cells were transiently transfected with either expression vectors for GFP-250 
or GFP-v-ErbA, and immunostained with antibodies specific for hsp70 or ubiquitin (Fig. 6B 
and 6C). To maximize aggresome formation, a portion of the cells were also treated with the 
proteosome inhibitor MG132. A subpopulation of Hsp70 colocalized with GFP-250 and 
GFP-v-ErbA in the presence or absence of MG132 in cells with aggregated foci (Fig. 6B). 
Our results showing colocalization of hsp70 with GFP-250 are consistent with the 
previously reported observations by Garcia-Mata et al. (1999), and are consistent with other 
published data on the recruitment of hsp70 as well as other classes of molecular chaperones 
to aggresomes (Garcia-Mata et al., 1999; Wigley et al., 1999). Colocalization of hsp70 with 
GFP-v-ErbA therefore provides additional evidence that foci formed by v-ErbA are 
aggresomes.
Ubiquitin was not observed to colocalize with either GFP-250 or GFP-v-ErbA (Fig. 6C). 
There are inconsistent reports of ubiquitin localization to aggresomes. GFP-250 forms 
aggresomes without being ubiquitinated (Garcia-Mata et al., 1999; Kawaguchi et al., 2003); 
likewise superoxide dismutase (SOD)-containing aggresomes do not appear to contain 
ubiquitinated proteins (Johnston et al., 2000). Aggresomes formed in cells expressing CFTR 
(Johnston et al., 1998) (Wigley et al., 1999); influenza virus nucleoprotein (Antón et al, 
1999), mutant surfactant protein C (Kabore et al., 2001), malin and laforin (Mittal et al., 
2007), and rhodopsin (Saliba et al., 2002) do, however, react with antibodies to 
polyubiquitin, suggesting that proteins within these inclusions are ubiquitinated. Our 
findings that neither GFP-250 nor GFP-v-ErbA colocalize with ubiquitin, further indicate 
that ubiquitin may not always be a requirement for aggresome formation or protein turnover 
by this pathway. The variability in the association of ubiqutin with aggresomes as reported 
may also suggest substrate-specific recruitment of components of the protein degradation 
and folding machinery.
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2.7 Mitochondria are recruited to v-ErbA aggresomes
Microtubules provide the tracks for intracellular trafficking and regulate the distribution of 
cellular organelles, which are normally localized throughout the cytosol. The accumulation 
of aggregrated proteins causes disorganization of the microtubule network and leads to 
retraction of mitochondria from the cell periphery to the area of the aggresome and viral 
replication factories (Bauer and Richter-Landsberg, 2006; Heath et al., 2001; Mittal et al., 
2007; Muqit et al., 2006; Nozawa et al., 2004; Wileman, 2007). It is hypothesized that 
mitochondria are recruited to aggresomes to provide energy for the processes of protein 
folding and/or protein degradation (Waelter et al., 2001). Both the 20S proteasome subunit 
and chaperones have been shown to localize to the aggresome (Garcia-Mata et al., 1999) 
(and this paper). These structures both require the use of ATP to function; thus, it is 
plausible that mitochondria are retracted towards aggresomes to provide energy.
Colocalization of mitochondria with GFP-250 and GFP-v-ErbA aggresomes and pre-
aggresomal structures was assessed by staining cells with MitoTracker Red, a 
mitochondrion-selective dye. Mitochondria were distributed throughout the cytosol of 
untransfected cells (Fig. 7A), and in cells transfected with expression vectors for EGFP 
(Figure 7B) and GFP-TRα1 (Fig. 7C), as a control. In striking contrast, in 61% of cells that 
formed GFP-250 aggresomes, these foci colocalized with clusters of mitochondria that were 
retracted from the cell periphery (Fig. 7D).
In a prior study, when we analyzed cells where v-ErbA was present in punctate foci 
throughout the cytoplasm, we did not detect colocalization of these pre-aggresomal 
inclusions of v-ErbA with mitochondria (Bonamy et al., 2005). However, since our prior 
analysis did not examine mature, fully-formed aggresomes, we re-visited the question of 
colocalization of v-ErbA-containing aggresomes with mitochondria. Here, we observed 
colocalization of v-ErbA with mitochondria in 83% of cells that formed mature aggresomes 
(Fig. 7E). These findings indicate that both GFP-250 and GFP-v-ErbA aggresomes recruit 
mitochondria.
2.8 Deletion of the Gag sequence leads to nuclear retention of v-ErbA and decreases the 
recruitment of v-ErbA to aggresomes
Many viruses replicate in intracellular compartments, which are thought to increase 
efficiency of replication by isolating the viral components. These compartments, known as 
viral factories, are similar to aggresomes in that they rearrange vimentin, travel along the 
microtubule tracks, converge at the MTOC, and recruit chaperones, ubiquitin, and 
mitochondria (Arnaud et al., 2007). Additionally, the formation of viral factories, like 
aggresomes, is inhibited by the overexpression of p50/dynamitin and treatment with 
nocodazole (Wileman, 2006). Because v-ErbA is a retroviral oncoprotein, studying its 
cytoplasmic inclusions offers valuable insight in the study of both aggresomes and viral 
factories. As noted earlier, v-ErbA is expressed by AEV as a Gag-v-ErbA fusion protein 
(Sap et al., 1986). The Gag sequence is required for the biological activity of the 
oncoprotein (Erickson and Liu, 2009), and it contains a strong nuclear export sequence 
(DeLong et al., 2004). In a virus, Gag is involved in forming the viral capsid. Thus, it is 
possible that the Gag sequence serves as an aggresome targeting sequence; like other viral 
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components, it may be recognized by the dynein motors, which carry the protein along the 
microtubule tracks towards the nucleus.
To investigate the role of the Gag sequence in the subcellular localization of v-ErbA, cells 
were transiently transfected with GFP-ΔGag-v-ErbA (Gag sequence deleted) and viewed by 
fluorescence microscopy (Fig. 8A). Greater than 50% of cells expressing GFP-v-ErbA 
(containing Gag sequence) contain large cytoplasmic inclusions (e.g. see Fig. 3). In contrast, 
ΔGag-v-ErbA showed a significant nuclear population, a much more diffuse cytoplasmic 
distribution (Fig. 8B), and only a small percentage of cells (~1%) showed foci within the 
cytoplasm (Fig. 8C, also compare Fig. 8A with Figs. 1A and 2B). However, of these cells 
with cytoplasmic foci, 93.5% showed colocalization of TRα1 with ΔGag-v-ErbA in cells co-
expressing mCherry-tagged TRα1 and GFP-ΔGag-v-ErbA (Fig. 8C and 8D). These findings 
are consistent with our prior studies reporting that v-ErbA sequesters TRα1 in cytoplasmic 
foci by forming heterodimers (Bonamy et al., 2005).
Interestingly, YFP-tagged Gag (1–70), which localizes entirely to the cytoplasm (DeLong et 
al., 2004), formed multiple foci in the cytoplasm of 30% of cells. Thus, it is possible that the 
N-terminal 70 amino acids of AEV Gag may play a role in promoting the formation of these 
cytoplasmic foci also characteristic of v-ErbA. However, Gag alone is unable to sequester 
TRα1 in foci, presumably because Gag and TRα1 do not physically interact in situ. In cells 
co-expressing mCherry-TRα1 and YFP-Gag (1–70) there was no colocalization of the two 
proteins (Fig. 8C and 8E). YFP-Gag (1–70) remained localized to the cytoplasm and TRα1 
remained localized to the nucleus. Although the Gag protein does appear to contribute to the 
cytoplasmic localization of v-ErbA and its recruitment to aggresomes, our data indicate that 
it is not the only contributing factor. When Gag is deleted, v-ErbA becomes more localized 
to the nucleus and, as a consequence, less of the oncoprotein is available for aggresome 
formation because of its altered distribution.
2.9 Dynamics of v-ErbA aggresome formation
Although mainly cytoplasmic at steady-state, it is well documented that v-ErbA has a 
nuclear function and undergoes nucleocytoplasmic shuttling (Bonamy et al., 2005; Bunn et 
al., 2001; DeLong et al., 2004). Leptomycin B (LMB), a specific inhibitor of the export 
receptor CRM1/exportin 1 (Kutay and Güttinger, 2005), blocks nuclear export of v-ErbA; 
LMB treatment results in complete nuclear localization of v-ErbA, indicating that v-ErbA 
utilizes a CRM1-dependent nuclear export pathway (Bunn et al., 2001). We were thus 
interested in understanding the movements of v-ErbA between cytoplasmic 
subcompartments and the nucleus. To determine the dynamics of aggresome formation by v-
ErbA, we investigated aggresome formation reversibility (Fig. 9). After treatment with LMB 
for 5 h, pre-existing cytoplasmic foci disappeared and GFP-v-ErbA showed a primarily 
nuclear localization in 87% of cells in a time dependent manner, suggesting that aggresome 
formation is dynamic and reversible (compare Fig. 9A and 9C with Fig. 9B and 9D). The 
number of cells with aggregates remained constant over time in untreated cells; whereas, the 
number of cells with aggregates decreased dramatically in cells treated with LMB (Fig. 9E), 
correlating with nuclear accumulation of v-ErbA.
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These studies were carried out on cells fixed at specific time points, thus it was not possible 
to track the fate of a particular cell. To further investigate the dynamics at single-cell 
resolution, we carried out kinetic experiments in live cells. Real time analysis in living cells 
confirmed that aggregates were highly mobile; there was disappearance of small aggregates 
and diffuse accumulation of v-ErbA in the nucleus in the presence of LMB (Fig. 9F, 
supplementary Video S1); however, large aggregates did not dissociate and typically during 
the time course for cells with large aggregates, cell death occurred (Fig. 9G, supplementary 
Video S2). These findings suggest that small aggregates are mobile and reversible, but 
formation of mature aggresomes is an end-point.
3. Discussion
Previously we showed that a subpopulation of the v-ErbA oncoprotein (Gag-v-ErbA) 
accumulates in cytoplasmic foci and sequesters a significant fraction of TRα1 in these foci 
in transfected mammalian cells, contributing to its oncogenic properties (Bonamy and 
Allison, 2006; Bonamy et al., 2005). Here, we show that cytoplasmic foci are also present in 
chicken erythroblasts that are transformed with AEV and express native v-ErbA. We show 
that these foci represent targeting of v-ErbA to classic aggresomes. v-ErbA foci colocalize 
with aggresomal markers, are dependent on microtubule transport for their formation, 
disrupted the intermediate filament meshwork composed of vimentin and were enhanced in 
size upon treatment with proteasome inhibitors. Our studies thus highlight the complexity of 
v-ErbA’s mode of action. v-ErbA is a highly mobile protein that trafficks between multiple 
cellular compartments and carries out distinct activities within each compartment. The first 
two compartments are well-documented in the literature: a diffuse cytosolic location where 
v-ErbA is thought to dysregulate the mTOR (mammalian target of rapamycin) and TGF-β 
pathways (Erickson and Liu, 2009; Gonin-Giraud et al., 2008) and a nuclear location where 
it interacts with target genes (Bresson et al., 2007; Ventura-Holman et al., 2008). The third 
compartment, described here, is a perinuclear inclusion characterized as an aggresome. In 
addition to contributing to its dominant negative activity, trafficking of v-ErbA to 
aggresomes may play a role in turnover of the oncoprotein or, in the complete retrovirus, in 
viral replication and assembly.
3.1 Dynamics and morphology of v-ErbA aggresomes
A striking feature of v-ErbA foci is their highly mobile nature as they move along 
microtubule tracks, and the appearance and disappearance of small aggregates. Other 
proteins have also been shown to exchange rapidly between aggregates and a soluble pool 
(Fu et al., 2005; Mignot et al., 2007; Opazo et al., 2008). Importantly, we observed the 
disappearance of small v-ErbA aggregates in cells treated with the nuclear export inhibitor 
LMB, whereas cells with large perinuclear aggresomes typically underwent cell death 
during imaging. These observations of aggresome dynamics provide a plausible explanation 
for the apparent absence of fully-formed v-ErbA aggresomes in HD3 cells. It is likely that 
there is some mechanism in this AEV-transformed erythroblast cell line to prevent large 
aggregates from forming, thus allowing these cells to continue to proliferate in culture.
Aggresome formation is generally categorized into two broad categories: spherical (Garcia-
Mata et al., 1999; Garcia-Mata et al., 2002; Heath et al., 2001; Johnston et al., 1998; 
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Kuemmerle et al., 1999), or “ribbon-like” (Ardley et al., 2004; Fu et al., 2005; Mignot et al., 
2007). The criteria for formation of either of these two distinct morphologies have yet to be 
determined. v-ErbA inclusions typically formed a “ribbon-like” shape, but coalesce into a 
more spherical shape in cells treated with MG132. Spherical aggresomes formed by mutant 
CFTR also are only observed when induced by proteasome inhibitors (Johnston et al., 1998). 
These results suggest that the final aggresomal morphology for v-ErbA is not always 
reached after 48 h in cells with active proteasomes. Regardless of the effect on aggregate 
morphology, it is evident from the results presented here that protein degradation by the 
proteasome is critical for clearance of v-ErbA from the cell, as well as for the T3-dependent 
clearance of TRα1.
Trafficking of v-ErbA aggregates occurs by microtubule-mediated transport. HDAC6 may 
act as an adaptor protein linking polyubiquinated proteins to the dynein motor complexes for 
transport (Sha et al., 2009). However, we did not detect ubiquitin or dynein in v-ErbA 
aggresomes. The question thus remains of why HDAC6 is present in v-ErbA aggresomes. In 
addition to its function as an adaptor, HDAC6 has also been shown to deacetylate hsp90 and 
modulate its chaperone activity (Boyault et al., 2007). Hsp90 also partially co-localizes with 
aggresomes (Diaz-Griffero et al., 2006), and is known to form cytoplasmic complexes with 
v-ErbA (Privalsky, 1991), thus colocalization of HDAC6 with v-ErbA aggresomes could be 
due to association with hsp90 as opposed to interaction with ubiquitinated proteins and 
dynein. It remains to be determined whether this is the case.
3.2 Significance of targeting of v-ErbA to aggresomes
Targeting of v-ErbA to aggresomes may be a cellular response to the accumulation of the 
oncoprotein in the cytoplasm, thus serving as a quality control mechanism to sequester the 
mutant protein for turnover and disposal by the proteasome machinery. Our data show that 
mitochondria are recruited to v-ErbA aggresomes, raising some intriguing questions about 
the functional significance of such recruitment. It is hypothesized that mitochondria are 
recruited to aggresomes to provide energy for the processes of protein folding and/or protein 
degradation (Waelter et al., 2001). Alternatively, this retraction of mitochondria from the 
cell periphery could be a side-effect of disorganization of the cytoskeleton, due to vimentin 
redistribution.
Both the 20S proteasome subunit and chaperones have been shown to localize to the 
aggresome (Garcia-Mata et al., 1999) (and this paper); however, proteasome-mediated 
degradation is not thought to be very efficient at the aggresome (Garcia-Mata et al., 2002). 
Autophagy has been proposed to be a more effective system for degradation; however, 
autophagy-mediated clearance of aggresomes is not a universal phenomenon and appears to 
be dependent on the nature of the cytoplasmic inclusions (Wong et al., 2008). Ultimately, 
cells might undergo cell death if there is too great an accumulation of aggregated protein, as 
reported for cells containing mutant glial fibrillary acidic protein (GFAP) aggregates 
(Mignot et al., 2007), and as observed in our time-lapse recordings of v-ErbA dynamics. 
Clustering of mitochondria around aggresome-like structures may also coincide with 
markers of apoptosis in the cell (Cereghetti and Scorrano, 2006; Debure et al., 2003; Soo et 
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al., 2009). Thus, it is possible that mitochondria, once present at the MTOC, engage in 
signaling pathways that promote apoptosis.
Alternatively, recruitment of v-ErbA to aggresomes could be a remnant viral behavior for 
assembly at a viral factory. It is possible that a cellular response originally designed to 
reduce the potential toxicity of misfolded proteins is exploited by viruses as a means of 
concentrating structural proteins at sites of virus assembly (Prichard et al., 2008; Wileman, 
2006). Aggresome-forming viral factories have been shown to colocalize with the 
aggresomal marker GFP-250, disrupt vimentin intermediate filaments, and depend on intact 
microtubules for their formation, consistent with the properties of v-ErbA foci (Arnaud et 
al., 2007; Heath et al., 2001; Liu et al., 2005). The retroviral oncoprotein v-ErbA is a fusion 
protein that contains a portion of the AEV Gag sequence, which encodes structural proteins 
involved in the formation of the viral capsid. Prior studies in our lab have shown that the 
Gag portion of v-ErbA mediates CRM1-dependent nuclear export and that deletion of the 
Gag sequence results in a more nuclear localization of the protein (DeLong et al., 2004). 
Here, we show that deletion of the v-ErbA Gag sequence results in aggresome formation in 
only ~1% of cells, although this substantial decrease in aggresome formation is dependent in 
part on the shift of ΔGag-v-ErbA to a more nuclear distribution. The functional role of Gag-
mediated nuclear export of v-ErbA remains to be determined, but the results in this present 
study support the hypothesis that it could be a remnant behavior of viral assembly. The N-
terminal region of AEV Gag may promote enhanced targeting of v-ErbA to cytoplasmic 
aggresomes. Specific aggresome targeting sequences have been reported in the literature for 
other proteins, such as synphilin 1 (Zaarur et al., 2008). In contrast, the majority of Rous 
sarcoma virus (RSV) Gag accumulates in large, round structures in the cytoplasm called C-
terminal TSG101-induced cellular structures (TICS) (Johnson et al., 2005), which are 
similar, but not identical to, classic aggresomes, and do not colocalize with GFP-250.
3.3 Are aggresomes pathogenic or cytoprotective?
Dysregulation of quality control pathways for degradation of misfolded proteins has been 
implicated in numerous clinical diseases, including cystic fibrosis, neurodegenerative 
disorders and cancer (Heir et al., 2006; Iwata et al., 2005; Johnston et al., 1998; Kitami et 
al., 2006; Ma and Lindquist, 2001; Mittal et al., 2007; Muchowski, 2002; Olzmann and 
Chin, 2008; Opazo et al., 2008; Riley et al., 2002; Ross and Poirier, 2004; Saliba et al., 
2002; Sha et al., 2009; Shimohata et al., 2002; Simms-Waldrip et al., 2008; Taylor et al., 
2003; Waelter et al., 2001; Winton et al., 2008). Despite their prevalence in disease and their 
being a focus of many detailed studies, there are a number of remaining questions about 
aggresome formation and the functional significance of these structures.
Recently, it has been suggested that there are multiple compartments in addition to the 
classic aggresome to which misfolded proteins can be trafficked. One report suggests that 
misfolded proteins partition between two distinct quality control compartments: juxtanuclear 
quality control (JUNQ) and insoluble protein deposit (IPOD) (Kaganovich et al., 2008). 
Aggresomes and another quality control compartment, the ER-associated compartment 
(ERAC), have features in common with the JUNQ compartment, but are proposed to differ 
in their architecture. In addition, nuclear aggresome-like structures form in cell lines 
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transfected with vectors expressing the puromycin resistance gene, suggesting that these 
vectors elicit an unexpected misfolded protein response (Moran et al., 2009). It is not yet 
clear whether all these inclusions represent related compartments or whether they have 
specialized functions (Bagola and Sommer, 2008).
Regardless of whether inclusions represent classical aggresomes or some related 
compartment, due to the high degree of correlation between aggregate formation and 
pathogenesis, it has been questioned whether these inclusions contribute to pathogenesis, or 
whether the underlying cause of pathogenicity is the lack of a functional protein. 
Aggresomes thus have been proposed to be cytoprotective, in part because they sequester 
deleterious, aggregrated proteins and may facilitate their elimination by autophagy (Green 
and Kroemer, 2009; Olzmann and Chin, 2008; Zhou et al., 2009). A number of studies have 
shown that reduced cytotoxicity is associated with aggresome formation (Arrasate et al., 
2004; Fortun et al., 2003; Iwata et al., 2005; Tanaka et al., 2004; Taylor et al., 2003). Even 
more recently, aggresome formation has been implicated as a physiologic mechanism to 
regulate certain native cellular proteins; for example, cellular inactivation of inducible nitric 
oxide synthase (iNOS) (Pandit et al., 2009; Sha et al., 2009).
Whether the association of v-ErbA with aggresomes is pathogenic, cytoprotective, or 
physiologic remains an enigma. If viewed as a mechanism of sequestering excess v-ErbA 
for proteasome-mediated degradation or autophagy, then formation of the aggresome would 
appear to be cytoprotective. If one only considered the nuclear function of v-ErbA, then 
aggresome formation could be proposed to protect cells from the dominant negative activity 
of v-ErbA on nuclear receptors in the nucleus. However, when the full spectrum of v-ErbA 
subcellular trafficking is taken into account, then aggresome formation would appear to have 
pathogenic consequences. It is well documented that v-ErbA can sequester TRα1 and the 
retinoid X receptor in cytoplasmic foci, preventing these nuclear receptors from regulating 
transcription of target genes and, thereby, increasing dominant negative activity (Bonamy 
and Allison, 2006; Bonamy et al., 2005, and the present study). It is of interest to note that 
other dominant negative variants of TR form cytoplasmic foci (Bunn et al., 2001; Lee and 
Mahdavi, 1993), suggesting that this altered distribution pattern plays a role in their 
repressive action. Furthermore, specific mutations of TR genes are closely associated with 
endocrine disorders as well as several types of human cancers (Chan and Privalsky, 2009; 
Chan and Privalsky, 2010), and functional loss of both TRα1 and TRβ promotes tumor 
development in a mouse model of thyroid cancer (Zhu et al., 2010). Considered together, it 
is tempting to speculate that mislocalization of these variants is integral to pathogenesis. 
Comprehensive analysis of the effects of known mutations in TR on intracellular trafficking 
should help to clarify the relative contribution of receptor mislocalization to dominant 
negative activity and pathogenesis.
Compartmentalization also plays an important role in dominant negative activity of several 
other proteins and is central to disease pathogenesis. For example, in autosomal dominant 
retinitis pigmentosa, aggresomes containing mutant rhodopsin have been shown to recruit 
the normal wild-type protein (Saliba et al., 2002). In addition mutant ELOV4 (Elongation of 
very long-chain fatty acids-4) protein exerts a dominant negative effect, forming aggregates 
with the wild-type protein and contributing to pathogenesis in autosomal dominant 
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Stargardt-like macular dystrophy (Vasireddy et al., 2005). Similarly, the adenoviral 
E1B-55K oncoprotein forms aggresomes that sequester sequence-specific single-stranded 
DNA-binding protein 2, p53, and the MRE11-RAD50-NBS1 complex (MRN) (Fleisig et al., 
2007; Liu et al., 2005). This stimulates the rate of proteasome-mediated degradation of 
MRN, thereby contributing to the protection of viral DNA from MRN activity.
In summary, the results presented here provide novel insight into the subcellular trafficking 
and function of the oncoprotein v-ErbA. In addition to rapid nucleocytoplasmic shuttling, 
the oncoprotein is trafficked along the aggresomal pathway, forming aggresomes that 
sequester and mislocalize nuclear receptors. In addition to mislocalizing nuclear receptors 
(Bonamy et al., 2005), v-ErbA also forms complexes with Smad4 and disrupts Smad4 
nuclear localization, which is necessary for a functional TGF-β pathway (Erickson and Liu, 
2009). Whether Smad4 is sequestered in aggresomes will be of interest to investigate. 
Finally, our studies contribute to a general understanding of the aggresome and its role in 
pathogenesis, cytoprotection, and protein turn-over. Although understanding of the precise 
molecular mechanisms remains limited, and many questions remain as to the underlying 
cellular mechanisms and means of regulation, the aggresome trafficking pathway is 
considered a viable target for treatment of neurodegenerative diseases (Olzmann and Chin, 
2008; Zhang et al., 2007) and cancer (Rodriguez-Gonzalez et al., 2008). A complex model 
of v-ErbA function across three separate cellular compartments is emerging; these results 
add to the depth of understanding of v-ErbA activity and highlight the importance of altered 
subcellular trafficking for oncogenic disruption of gene regulation.
4. Materials and Methods
4.1 Plasmids
The GFP-250 and GFP170* expression vectors were a generous gift from Elizabeth Sztul 
(University of Alabama) (Fu et al., 2005; Garcia-Mata et al., 1999). The aggresomal marker 
GFP-250 is composed of GFP fused at its C-terminus to the first 250 amino acids of p115, a 
protein involved in the transport of cargo from the endoplasmic reticulum to the Golgi 
(Nelson et al., 1998). GFP170* is composed of GFP fused to amino acids 566–1375 of the 
Golgi Complex Protein (GCP)-170, which is also known as golgin-160 (Fu et al., 2005; 
Hicks and Machamer, 2002). GFP and DsRed2-tagged v-ErbA, GFP-TRα1, GFP-Δ Gag-v-
ErbA, and YFP-Gag (1–70) expression vectors have been previously described (Bonamy et 
al., 2005; Bunn et al., 2001; DeLong et al., 2004). Myc-tagged p50/dynamitin (pCMV 
H50myc) was a generous gift from Richard Vallee (Columbia University). The Dendra2-v-
ErbA expression vector was prepared by subcloning the v-ErbA coding region from GFP-v-
ErbA into Dendra2-C (Evrogen). The mCherry-TRα1 expression vector was prepared by 
subcloning the TRα1 coding region from GFP-TRα1 into mCherry-C1 (Clontech). The 
GFP-GST-GFP expression vector consists of the glutathione-S-transferase (GST) and GFP 
coding regions subcloned in-frame into EGFP-C1 (Clontech). The expression vector for 
GFP-tagged glucocorticoid receptor (GFP-GR) was obtained from Bryce Paschal 
(University of Virginia) (Black et al., 2001).
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4.2 Cell culture, transfections, and drug treatments
HeLa cells (human cervix epithelioid carcinoma; ATCC CCL-2) were grown and 
maintained at 37°C and 5% CO2 in Minimum Es sential Medium (Gibco), supplemented 
with 10% fetal bovine serum (Invitrogen) and intermittently supplemented with 100 U/mL 
penicillin and 100 μg/mL streptomycin. HD3 cells (chicken erythroblasts transformed with 
AEV) were a generous gift from Xuedong Liu (University of Colorado-Boulder). HD3 cells 
were maintained in DMEM (Gibco) supplemented with 8% fetal bovine serum and 2% 
chicken serum (Invitrogen; heat inactivated for 1 h at 56°C).
For transient transfection assays, 1–3 × 105 HeLa cells per well were added to each well of a 
6-well plate with glass coverslips (Fisher) and incubated at 37°C for approximately 24 h. 
Various combinations of plasmid expression vectors were introduced using either 
Lipofectamine or Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
recommendations. Cells were fixed 24–48 h post-transfection and analyzed by fluorescence 
microscopy. In some experiments, cells were treated with 2–4 nM leptomycin B (Sigma) or 
vehicle (methanol) for 1–5 h, 100 nM 3,3′,5-triiodo-L-thyronine (T3) (Sigma), the 
proteasome-inhibiting drug MG132 (10 μg/ml, Sigma; or 10 μM, Calbiochem), the 
microtubule-disrupting drug nocodazole (10 μg/ml, Sigma), or an equivalent volume of 
vehicle (DMSO) for 12–20 hr post-transfection.
4.3 Fixation, immunofluorescence, and organelle staining
Approximately 24–48 hours after transfection, cells were fixed in 3.7% formaldehyde and 
permeabilized with 0.2% Triton-X-100. Antibodies used were as follows: anti-v-ErbA/c-
ErbA, 1:100 (FL-408, Santa Cruz Biotechnologies); Cy3-conjugated anti-vimentin, 1:200 
(Sigma); anti-c-myc, 1:500 (Clontech); anti-20S proteasome ‘core’ subunits, 1:500 
(BioMol); anti-HDAC6, 1:100 (Santa Cruz Biotechnologies); anti-ubiquitin, 1:100 
(Calbiochem); anti-Hsp70 1:50 (Stressgen); Cy3-goat anti-mouse or Cy3-goat anti-rabbit, 
1:500 (Zymed Laboratories); and FITC-conjugated anti-β-tubulin, 1/10 (Sigma). To 
visualize mitochondria, cells were treated with 10 nM MitoTracker Red (Molecular Probes) 
approximately 48 h post-transfection. Upon addition of MitoTracker Red, cells were 
incubated at 37°C for 30 min. After processing, coverslips were mounted onto microscope 
slides in Fluoro-Gel II (Electron Microscopy Sciences) containing the DNA counter stain 
DAPI (4, 6-diamino-2-phenylindole).
4.4 Cell scoring and statistical analysis
For some experiments, prepared slides were analyzed with an Olympus fluorescence 
microscope. Cells were photographed with a Cooke SensiCamQE digital camera. IP Lab 
software and Adobe Photoshop CS were used to pseudocolor, and layer the captured images. 
For other experiments, images were collected from an inverted Nikon ECLIPSE TE 2000-E 
fluorescence microscope (Sigma, Melville, NY). A Nikon Ultraviolet Excitation: UV-2E/C 
filter block for DAPI visualization and a Blue Excitation: B-2E/C filter block for G3BP-GFP 
visualization were used with a Nikon Plan Apo 60x objective. A CoolSNAP HQ2 CCD 
camera (Photometrics) and NIS-Elements AR software (Nikon) were used for image 
acquisition and primary image processing.
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At least 2–3 replicate transfections were performed, with a minimum of 100 cells scored per 
replicate. Results were tested for statistical significance using SPSS (v. 16). Data were 
analyzed for frequency distribution using a Chi-Square test; a p-value of 0.001 or less was 
considered significant.
4.5 Immunoblotting
HeLa cells were seeded onto 100 mm plates (7 × 105 cells per plate) in MEM supplemented 
with charcoal-dextran stripped fetal bovine serum (Hyclone). Sixteen hours post-
transfection, cells were treated with vehicle (DMSO), T3 (100 nM, Sigma), or MG132 (10 
μM, Calbiochem) for 16.5 hours. Subsequently, whole cell lysates were prepared using the 
Active Motif Nuclear Extract Kit, according to the manufacturer’s instructions. For v-ErbA, 
both the supernatant and pellet fractions from each lysis were analyzed by SDS-PAGE; 
similar amounts of v-ErbA were distributed between the insoluble versus soluble fraction. 
The protein concentration was determined by spectrophotometry. Forty μg of whole cell 
extract per treatment were resolved by 8% SDS-PAGE and transferred to a PVDF 
membrane (GE Healthcare) by semi-dry electroblotting for immunoblot analysis with anti-
GFP (1:200) (Santa Cruz Biotechnology) and anti-β-tubulin (1:200) (Santa Cruz 
Biotechnology) antibodies, followed by chemilumiscent detection using ECL Plus. Protein 
size was monitored using Pre-Stained Kaleidoscope Protein Standards (Bio-Rad).
4.6 Live cell imaging
After transfection, cells were used for microscopy within 48 h. Prior to mounting in an 
enclosed perfusion chamber (Bioptechs, Butler, PA), coverslips were incubated in 2 ml 
complete media containing 2–4 nM leptomycin B (LMB) (Sigma) or vehicle (0.1% 
methanol) for 30 min. Coverslips were then washed with 2 ml Dulbecco’s phosphate 
buffered saline (D-PBS) and mounted. For the duration of each experiment, cells were 
incubated in MEMα (without phenol red) containing 2–4 nM LMB or vehicle (0.1% 
methanol). All life cell imaging was performed using the inverted Nikon ECLIPSE TE 
2000-E fluorescence microscope.
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Fig. 1. 
A subpopulation of the oncoprotein v-ErbA localizes to punctate foci in erythroblasts 
transformed with AEV. (A) The distribution of v-ErbA in transfected HeLa cells ranges 
from whole cell (with a nuclear subpopulation) to a mainly cytoplasmic distribution, 
localized in punctate, perinuclear foci. HeLa cells were transfected with DsRed2-v-ErbA 
expression vectors. 24h post-transfection, cells were fixed and analyzed by fluorescence and 
differential interference contrast (DIC) microscopy. Nuclei were stained for DNA with 
DAPI (blue). (B) Native, virally-expressed v-ErbA forms cytoplasmic foci in chicken 
erythroblasts transformed with AEV (HD3 cells). Native v-ErbA was visualized in HD3 
cells by immunostaining (red).
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Fig. 2. 
The oncoprotein v-ErbA colocalizes with aggresomal markers. (A) Fluorescent proteins 
alone and control GFP-tagged fusion proteins do not localize to cytoplasmic foci. HeLa cells 
were transfected with expression vectors for GFP, DsRed2, Dendra, GFP-GST-GFP, or 
GFP-glucocorticoid receptor (GFP-GR). Twenty-four hours post-transfection, cells were 
fixed and analyzed by fluorescence microscopy. Nuclei were stained for DNA with DAPI 
(blue). (B) A subpopulation of DsRed2-tagged and Dendra2 (monomeric fluorescent 
protein)-tagged v-ErbA localizes to cytoplasmic foci. HeLa cells were cotransfected with 
either DsRed2-tagged or Dendra2-tagged v-ErbA expression vectors and processed as 
described in (A). (C) Localization of the aggresomal marker GFP-250 24 h post-
transfection. (D) Colocalization of the aggresomal markers GFP-250, GFP170*, and 
DsRed2-v-ErbA. HeLa cells were cotransfected with either GFP-250 or GFP170*, and 
DsRed2-v-ErbA expression vectors. Either 24 h or 48 h post-transfection, as indicated, cells 
were fixed and analyzed by fluorescence microscopy. In the merged images, yellow 
indicates colocalization between either GFP-250 or GFP170* and DsRed2-v-ErbA. (E) Bar 
graph summarizing colocalization data for GFP-250 and DsRed2-v-ErbA. Forty-eight hours 
post-transfection, DsRed2-v-ErbA and GFP-250 completely colocalized (Total) in 59 ± 4% 
of cells and partially colocalized (Partial) in 38 ± 4% of cells (n=3 replicate transfections, 
313 cells scored). Error bars indicate ±SEM.
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Fig. 3. 
Formation of v-ErbA foci is microtubule-and dynein-dependent. (A) Treatment with 
nocodozole disrupts microtubules. HeLa cells were either left untreated, treated with DMSO 
(vehicle control), or treated with nocodozole (+NOC) for 20 h. Microtubules were visualized 
by immunostaining with Cy3-tagged anti-β-tubulin (red). Nuclei were stained for DNA with 
DAPI (blue) (B) Microtubule disruption prevents the formation of coalesced v-ErbA foci. 
HeLa cells were transfected with an expression vector for GFP-v-ErbA, and 16 h post-
transfection were treated with nocodazole for 20 h. +NOC (diffuse), nocodazole-treated cell 
forming diffuse aggregates; +NOC (small aggregates), nocodazole-treated cell forming 
small aggregates, uniform in size; −NOC, untreated cell forming large juxtanuclear foci. (C) 
Bar graph summarizing the effect of nocodozole on v-ErbA foci size. Upon nocodazole 
treatment, there was a significant shift (p < 0.001) in frequency distribution from larger foci 
to smaller, more diffuse foci. Error bars indicate ±SEM (n=2 replicates, 200 cells scored). 
(D–G) Overexpression of p50/dynamitin disrupts aggresome formation. (D) HeLa cells were 
transfected with GFP-250 expression vector alone (−Dynamitin) or together with Myc-
tagged p50/dynamitin expression vector (+Dynamitin). After 24–48 h, cells were fixed, 
immunostained with anti-Myc antibodies (red) and analyzed by fluorescence microscopy. 
Blue, nucleistained for DNA with DAPI. In the absence of p50/dynamitin, GFP-250 formed 
mature aggresomes. In the presence of p50 dynamitin, smaller aggregates formed. (E) Bar 
graph summarizing the effect of p50/dyamitin on GFP-250 aggresome formation. Error bars 
indicate ±SEM (n=3 replicates, 100 cells scored per replicate). (F) HeLa cells were 
transfected with GFP-v-ErbA expression vector alone (−Dynamitin) or together with Myc-
tagged p50 dynamitin expression vector (+Dynamitin). After 24–48 h, cells were fixed and 
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analyzed by fluorescence microscopy. In the absence of p50/dynamitin GFP-v-ErbA formed 
mature aggresomes. In the presence of p50/dynamitin, smaller aggregates formed. (G) Bar 
graph summarizing the effect of p50/dynamitin on GFP-v-ErbA aggresome formation. Error 
bars indicate ±SEM (n=3 replicates, 100 cells scored per replicate).
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Fig. 4. 
v-ErbA foci disrupt vimentin intermediate filaments and colocalize with HDAC6. (A) In 
untransfected cells, the vimentin distribution pattern was filamentous and dispersed 
throughout the cell. After fixation, HeLa cells were stained with a Cy3-conjugated antibody 
against vimentin (red); nuclei were stained for DNA with DAPI (blue). (B) v-ErbA foci 
cause a disruption of vimentin filaments. HeLa cells transfected with GFP-v-ErbA were 
immunostained for vimentin 48 h post-transfection (n=3, > 300 cells scored). Green, 
distribution of GFP-v-ErbA; Red, distribution of Cy3-conjugated antibody against vimentin; 
Merge, layered image of GFP-v-ErbA and Cy3-vimentin; Blue, nuclei stained for DNA with 
DAPI. Cells transfected with GFP-v-ErbA showed a reorganization and collapse of vimentin 
around the area of aggregated protein. (C, D) GFP-250 and GFP-v-ErbA aggresomes are not 
enriched for dynein. HeLa cells were transfected with either GFP-250 (C) or GFP-v-ErbA 
(D), as indicated, and 16 h post-transfection treated with the proteasome inhibitor MG132 
for 20 h (+MG132) to enhance mature aggresome formation, or with DMSO, the vehicle 
control (−MG132). Subsequently, cells were fixed and immunostained with anti-dynein 
antibodies (red) and analyzed by fluorescence microscopy for colocalization (yellow). (E) 
Colocalization of GFP-250 aggresomes with HDAC6. HeLa cells transfected with GFP-250 
(n=103 cells scored) were fixed and immunostained with anti-HDAC antibodies (red) and 
analyzed for colocalization (yellow) by fluorescence microscopy. (F) Colocalization of v-
ErbA aggresomes with HDAC6. HeLa cells transfected with GFP-v-ErbA (n=100 cells 
scored) were fixed and immunostained with anti-HDAC antibodies (red) and analyzed for 
colocalization (yellow) by fluorescence microscopy.
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Fig. 5. 
Proteasome inhibition increases v-ErbA aggregate size but does not induce TRα1 
cytoplasmic foci. (A) To determine whether the size of v-ErbA foci would increase in 
response to proteasome inhibition, 16 h post-transfection, HeLa cells expressing GFP-v-
ErbA were treated with the proteasome inhibitor MG132 for 20 h (+MG132), or with 
DMSO, the vehicle control (−MG132). Most of the large aggregates were spherical in 
morphology and coalesced into a single aggregate. (B) Bar graph summarizing the effect of 
MG132 treatment on v-ErbA aggregate size. There was a significant shift in frequency 
distribution from smaller aggregates to large aggregates (p< 0.001; n=2 replicate 
transfections, 200 cells scored). Error bars indicate ±SEM. (C) HeLa cells were transfected 
with expression vector for GFP-v-ErbA, in the presence (+MG) or absence (−MG) of the 
proteasome inhibitor MG132, as indicated. Forty-eight hours post-transfection, whole cell 
extracts were subject to Western blot analysis using anti-GFP antibodies, and anti-β-tubulin 
antibodies as an internal recovery control. Bio-Rad pre-stained Kaleidoscope protein 
molecular mass standards were used to confirm protein identity (GFP-v-ErbA, 102 kDa; β-
tubulin, 55 kDa). (D) The proteasome mediates degradation of TRα1. HeLa cells were 
transfected with expression vector for GFP-TRα1, in the presence (+T3) or absence (−T3) of 
thyroid hormone and/or in the presence (+MG) or absence (−MG) of the proteasome 
inhibitor MG132, as indicated. Forty-eight hours post-transfection, whole cell extracts were 
subject to Western blot analysis using anti-GFP antibodies, and anti-β-tubulin antibodies as 
an internal recovery control. Bio-Rad pre-stained Kaleidoscope protein molecular mass 
standards were used to confirm protein identity (GFP-TR, 73 kDa; β-tubulin, 55 kDa). (E) 
HeLa cells were transfected with expression vector for GFP-TRα1. 24 h post-transfection, 
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cells were fixed and analyzed by fluorescence microscopy. In the absence of thyroid 
hormone (−T3) fluorescence intensity was typically greater than in the presence of thyroid 
hormone (+T3). Images were captured using the same exposure times. (F) HeLa cells were 
transfected with expression vector for GFP-TRα1. After treatment with MG132 or DMSO, 
the vehicle control, cells were fixed and analyzed by fluorescence microscopy. In the 
presence of MG132 (+MG132), fluorescence intensity was typically much greater than in 
the absence of MG132 (−MG132), and some cells showed nuclear aggregates of TRα1.
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Fig. 6. 
v-ErbA foci colocalize with 20S proteasome subunits and Hsp70 but not with ubiquitin. (A) 
Colocalization of 20S proteasome subunits with GFP-250 and v-ErbA aggresomes. HeLa 
cells overexpressing GFP-250 (upper panels) or GFP-v-ErbA (lower panels) were fixed 48 h 
post-transfection and immunostained with anti-20S proteasome antibodies (red). In the 
merged images, yellow indicates colocalization; blue, nuclei stained with DAPI. (B) 
Colocalization of Hsp70 with GFP-250 (upper set of panels) and v-ErbA (lower set of 
panels) aggresomes. HeLa cells overexpressing GFP-250 or GFP-v-ErbA were treated with 
the proteasome inhibitor MG132 (+MG132) to enhance aggresome formation, or with 
DMSO (vehicle control, −MG132), then fixed and immunostained with anti-hsp70 
antibodies (red). In the merged images, yellow indicates colocalization; blue, nuclei stained 
for DNA with DAPI. (C) Ubiquitin does not colocalize with GFP-250 (upper set of panels) 
and v-ErbA (lower set of panels) aggresomes. HeLa cells overexpressing GFP-250 or GFP-
v-ErbA were treated with the proteasome inhibitor MG132 (+MG132) to enhance 
aggresome formation, or with DMSO (vehicle control, −MG132), then fixed and 
immunostained with anti-ubiquitin antibodies (red).
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Fig. 7. 
Mitochondria are recruited to v-ErbA aggregates. In untransfected cells (A), and in cells 
transfected with expression vectors for EGFP (B) and GFP-TRα1 (C) as controls, 
mitochondria were distributed throughout the cytosol. Untransfected or transfected HeLa 
cells were stained with MitoTracker Red to visualize mitochondria, then fixed and analyzed 
by fluorescence microscopy. Blue, nuclei stained for DNA with DAPI. In cells transfected 
with expression vectors for GFP-250 (D) or GFP-v-ErbA (E), mitochondria were retracted 
from the cell periphery and colocalized with aggresomes. In the merged images, yellow 
indicates colocalization.
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Fig. 8. 
The AEV Gag sequence plays a role in targeting of v-ErbA to aggresomes. (A) HeLa cells 
were transfected with expression vectors for GFP-ΔGag-v-ErbA (deletion of Gag sequence). 
24 h post-transfection, cells were fixed and analyzed by fluorescence microscopy. A 
representative example of the subcellular distribution of GFP-ΔGag-v-ErbA is shown. GFP-
ΔGag-v-ErbA was more nuclear than GFP-v-ErbA and had very few cytoplasmic aggregates 
compared with GFP-v-ErbA. Nuclei were stained for DNA with DAPI. (B) Bar graph 
summarizing the distribution pattern of ΔGag-v-ErbA. N, predominantly localized to the 
nucleus; C, predominantly localized to the cytoplasm; N=C, whole cell distribution (n=200 
Bondzi et al. Page 34
Mol Cell Endocrinol. Author manuscript; available in PMC 2015 November 05.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
cells scored). (C–E) Colocalization of TRα1 in cytoplasmic foci containing v-ErbA or 
ΔGag-v-ErbA, but not Gag (1–70). (C) HeLa cells were co-transfected with expression 
vectors for mCherry-TRα1 and GFP-v-ErbA (with Gag sequence), GFP-ΔGag-v-ErbA, or 
YFP-Gag (1–70). 24 h post-transfection, cells were fixed and analyzed for co-localization by 
fluorescence microscopy in cells with prominent cytoplasmic foci. In the merged images, 
yellow indicates colocalization; blue, nuclei stained with DAPI. (D) Bar graph summarizing 
the percentage of cells in which mCherry-TRα1 and GFP-ΔGag-v-ErbA were colocalized 
(n=100 cells scored per treatment). (E) Bar graph summarizing the percentage of cells in 
which mCherry-TRα1 and YFP-Gag (1–70) were colocalized (n=100 cells scored per 
treatment).
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Fig. 9. 
Dynamics of v-ErbA aggresome formation in the presence of leptomycin B (LMB). (A) In 
the absence of LMB (−LMB), v-ErbA has a predominantly cytoplasmic localization. HeLa 
cells were transfected with expression vector for GFP-v-ErbA. 16–20 h post-transfection, 
cells were treated for 0–5 h with vehicle (0.1% methanol), as indicated, fixed, stained for 
DNA with DAPI, and analyzed by fluorescence microscopy. (B) In the presence of LMB 
(+LMB), v-ErbA has a predominantly nuclear localization. HeLa cells were transfected with 
expression vector for GFP-v-ErbA. 16–20 h post-transfection, cells were treated for 1–5 h 
with leptomycin B (+LMB). (C) Bar graph summarizing the subcellular location of v-ErbA 
over time in the absence of LMB. Cyt, predominantly cytoplasmic; Cyt+Nuc, whole cell; 
Nuc, predominantly nuclear localization. (D) Bar graph summarizing the subcellular 
location of v-ErbA over time in the presence of LMB. (E) Bar graph summarizing the effect 
of LMB on v-ErbA aggregates over time. Error bars indicate ±SEM. (F–G) Time lapse 
imaging of dynamics of v-ErbA aggregates in single cells. HeLa cells were transfected with 
expression vector for GFP-v-ErbA. After 48 h, cells were subject to time-lapse imaging in 
the presence of LMB, with images acquired every 15 s for 6 h. Two Quick-Time movie files 
are attached as supplemental materials (Videos S1 and S2). (F) A panel of images from a 
cell with small aggregates, at time points indicated, during LMB treatment (see Video S1). 
(G) A panel of images from a cell with large aggregates, at time points indicated, during 
LMB treatment, ending in cell death (see Video S2). White arrowheads indicate movement 
of a small aggregate that coalesces with the large aggresome at the nuclear periphery.
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